Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.

Sotera Health Company

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CLEVELAND, MARCH 04, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC) (THE COMPANY) TODAY ANNOUNCED THE LAUNCH OF A SECONDARY OFFERING (THE OFFERING) OF 25 MILLIONSHARES OF ITS COMMON STOCK, PAR VALUE $0.01 PER SHARE. ALL 25 MILLION SHARES ARE BEING OFFERED FOR SALE BY CERTAIN AFFILIATES OF WARBURG PINCUS LLC (WARBURG PINCUS) AND GTCR LLC (GTCR) AS SELLING STOCKHOLDERS.

SOTERA HEALTH ANNOUNCES SECONDARY OFFERING OF COMMON STOCK

2025 NET REVENUES INCREASED 5.7% TO $1.164 BILLION , COMPARED TO 2024, OR 5.2% ON A CONSTANT CURRENCY BASIS 2025 NET INCOME INCREASED TO $78 MILLION OR $0.27 PER DILUTED SHARE, COMPARED TO NET INCOME OF $44 MILLION, OR $0.16 PER DILUTED SHARE, IN 2024 2025 ADJUSTED EBITDA (1) INCREASED 8.2% TO $594 MILLION, COMPARED TO 2024, OR 7.8% ON A CONSTANT CURRENCY BASIS 2025 ADJUSTED EPS (1) OF $0.86, AN INCREASE OF $0.16 PER DILUTED SHARE, COMPARED TO 2024 FULL-YEAR 2026 OUTLOOK: NET REVENUES GROWTH OF 5.0% TO 6.5% AND ADJUSTED EBITDA GROWTH OF 5.5% TO 7.0%, ON A CONSTANT CURRENCY BASIS CLEVELAND, FEB. 24, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (SOTERA HEALTH OR THE COMPANY) (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FOURTH-QUARTER AND FULL-YEAR 2025 AND ITS INITIAL 2026 OUTLOOK. FOURTH-QUARTER 2025 NET REVENUES INCREASED 4.6% TO $303 MILLION, COMPARED TO $290 MILLION IN THE FOURTH-QUARTER 2024.

SOTERA HEALTH DELIVERS 20TH CONSECUTIVE YEAR OF REVENUE GROWTH AND PROVIDES 2026 OUTLOOK

CLEVELAND, FEB. 17, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED ITS PLANS TO RELEASE ITS FINANCIAL RESULTS FOR THE FOURTH-QUARTER AND FULL-YEAR ENDED DECEMBER 31, 2025 BEFORE THE MARKET OPENS ON TUESDAY, FEBRUARY 24, 2026. FOLLOWING THE RELEASE, MANAGEMENT WILL HOLD A CONFERENCE CALL AT 9:00 A.M.

SOTERA HEALTH ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2025 EARNINGS RELEASE DATE

CLEVELAND, FEB. 05, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, ANNOUNCED TODAY IT HAS APPOINTED RICHARD G. KYLE AS A NEW INDEPENDENT DIRECTOR TO ITS BOARD OF DIRECTORS.

SOTERA HEALTH APPOINTS RICHARD KYLE TO THE BOARD OF DIRECTORS

CLEVELAND, JAN. 12, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (SOTERA HEALTH OR THE COMPANY) (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, IS PRESENTING TODAY AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.

SOTERA HEALTH TO SHOWCASE CONTINUED REVENUE GROWTH AND STRATEGIC VALUE CREATION AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

CLEVELAND, JAN. 07, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (SOTERA HEALTH OR THE COMPANY) (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ON MONDAY, JANUARY 12, 2026 AT 1:30 P.M.

SOTERA HEALTH TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

CLEVELAND, NOV. 06, 2025 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC) (THE COMPANY) TODAY ANNOUNCED THE LAUNCH OF A SECONDARY OFFERING (THE OFFERING) OF 30,000,000 SHARES OF ITS COMMON STOCK, PAR VALUE $0.01 PER SHARE. ALL 30,000,000 SHARES ARE BEING OFFERED FOR SALE BY CERTAIN AFFILIATES OF WARBURG PINCUS LLC (WARBURG PINCUS) AND GTCR LLC (GTCR) AS SELLING STOCKHOLDERS.

Q3 2025 NET REVENUES INCREASED 9.1% TO $311 MILLION , OR 8.0% ON A CONSTANT CURRENCY BASIS ( 1) , COMPARED TO Q3 2024 Q3 2025 NET INCOME OF $48 MILLION, OR $0.17 PER DILUTED SHARE, COMPARED TO NET INCOME OF $17 MILLION OR $0.06 PER DILUTED SHARE IN Q3 2024 Q3 2025 ADJUSTED EBITDA ( 1 ) INCREASED 12.2% TO $164 MILLION, OR 11.2% ON A CONSTANT CURRENCY BASIS, COMPARED TO Q3 2024 Q3 2025 ADJUSTED EPS ( 1) OF $0.26, AN INCREASE OF $0.09 PER DILUTED SHARE, COMPARED TO ADJUSTED EPS OF $0.17 IN Q3 2024 RAISING 2025 ADJUSTED EBITDA GROWTH RANGE TO 6.75% - 7.75% AND REAFFIRMING NET REVENUES OUTLOOK RANGE OF 4.5% - 6.0%, ON A CONSTANT CURRENCY BASIS CLEVELAND, NOV. 04, 2025 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (SOTERA HEALTH OR THE COMPANY) (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THREE- AND NINE-MONTHS ENDED SEPTEMBER 30, 2025. THIRD-QUARTER 2025 NET REVENUES INCREASED 9.1% TO $311 MILLION, COMPARED TO $285 MILLION IN THE THIRD-QUARTER 2024.

SOTERA HEALTH REPORTS STRONG THIRD-QUARTER AND YEAR-TO-DATE 2025 RESULTS

CLEVELAND, OCT. 21, 2025 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE THIRD-QUARTER ENDED SEPTEMBER 30, 2025 BEFORE THE MARKET OPENS ON TUESDAY, NOVEMBER 4, 2025. FOLLOWING THE RELEASE, MANAGEMENT WILL HOST A CONFERENCE CALL AT 9:00 A.M.

SOTERA HEALTH ANNOUNCES THIRD-QUARTER 2025 EARNINGS RELEASE DATE

CLEVELAND, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC) (THE COMPANY) TODAY ANNOUNCED THE LAUNCH OF A SECONDARY OFFERING (THE OFFERING) OF20,000,000 SHARES OF ITS COMMON STOCK, PAR VALUE $0.01 PER SHARE. ALL20,000,000 SHARES ARE BEING OFFERED FOR SALE BY CERTAIN AFFILIATES OF WARBURG PINCUS LLC (WARBURG PINCUS) AND GTCR LLC (GTCR) AS SELLING STOCKHOLDERS. NO OTHER ENTITIES, AND NO INDIVIDUALS, ARE SELLING SHARES IN THE OFFERING. THE COMPANY IS NOT OFFERING ANY SHARES IN THE OFFERING AND WILL NOT RECEIVE ANY OF THE PROCEEDS FROM THE OFFERING. THE COMPANY WILL PAY THE EXPENSES OF THE OFFERING PURSUANT TO ITS OBLIGATIONS UNDER ITS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT.

Sotera Health Company

SHC

Price

Financial Reports

No items found.

Press Releases

Sotera Health Company

SHC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SHC